Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus ATNAA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus ATNAA.
ANTIZOL vs ATNAA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Atropine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of parasympathetic nervous system. Pralidoxime is an acetylcholinesterase reactivator; it displaces the phosphoryl group from the inhibited enzyme, allowing restoration of cholinesterase activity.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
Initial dose: 0.4 mg (1 mL) IV/IM/SC, repeated every 2-3 minutes as needed. Subsequent doses: 2 mg (5 mL) IV/IM/SC if opioid-induced respiratory depression recurs.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
Atropine: 2-4 hours in adults (prolonged in elderly and children). Pralidoxime: 1.2-2.6 hours (shorter due to rapid renal clearance). Clinical context: half-lives are extended in organophosphate poisoning due to altered distribution.
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Renal: predominantly as metabolites and unchanged drug; approximately 50-70% of atropine and up to 97% of pralidoxime are excreted renally. Biliary/fecal: minor route for atropine (<5%).
Category C
Category C
Antidote
Antidote